rozanolixizumab

FDA Drug Profile

Drug Details

Generic Name
rozanolixizumab
Brand Names
N/A
Application Number
Sponsor
SAMSUNG BIOLOGICS Co., Ltd.
NDC Codes
1
Dosage Forms
LIQUID
Routes
N/A
Active Ingredients
ROZANOLIXIZUMAB-NOLI

Indications and Usage

1 INDICATIONS AND USAGE RYSTIGGO is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. RYSTIGGO (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. ( 1 )